Advanced hepatocellular carcinoma research hub
4 indexed studies · 2 currently recruiting
- authorisedPhase II and Phase III (Integrated)
The HCC patient-journey study: a prospective, adaptive, master protocol, to assess the value of the available sequences of treatment for patients with advanced hepatocellular carcinoma. The Journey of liver cancer patient - J-LI
This study looks at advanced liver cancer. Doctors want to find the best order in which to give approved cancer medicines. By testing different treatment paths, the trial aims to help patients live longer, manage their symptoms, and discover which drug combinations offer the best quality of life.
Italy - recruitingPhase I and Phase II (Integrated)- Other
A phase I study evaluating safety and efficacy of Hepatic Intra- Arterial administration of ipilimumab in combination with Intra- venous nivolumab for advanced Hepatocellular carcinoma (HIPANIV)
This study is looking at a new way to treat advanced liver cancer. It combines two existing medicines, ipilimumab and nivolumab, given in a special way to see if it's safe and works well. This early-stage trial aims to find the best dose.
France - recruitingTherapeutic exploratory (Phase II)
A Phase 2, Randomized, Open-label Study of Relatlimab in Combination with Nivolumab in Participants with Advanced Hepatocellular Carcinoma who are Naive to IO Therapy but Progressed on Tyrosine Kinase Inhibitors (RELATIVITY-073)
This study is looking at a new combination of two medicines, nivolumab and relatlimab, for adults with advanced liver cancer that has progressed despite previous treatments. It aims to see how well this new combination shrinks tumors and if it's safe.
Romania · Poland · Spain - active not recruitingPHASE3
Durvalumab and Tremelimumab as First Line Treatment in Participants With Advanced Hepatocellular Carcinoma (HCC)
This study looks at two drugs, durvalumab and tremelimumab, as a first treatment for advanced liver cancer that can't be removed by surgery. Researchers want to see how safe and effective this combination is.
United States · France · Germany